Hod Tammy, Cerdeira Ana Sofia, Karumanchi S Ananth
Department of Medicine, Obstetrics & Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02214.
Department of Medicine, Obstetrics & Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02214 Gulbenkian Program for Advanced Medical Education, 1067-001 Lisbon, Portugal.
Cold Spring Harb Perspect Med. 2015 Aug 20;5(10):a023473. doi: 10.1101/cshperspect.a023473.
Preeclampsia is a pregnancy-specific disease characterized by new onset hypertension and proteinuria after 20 wk of gestation. It is a leading cause of maternal and fetal morbidity and mortality worldwide. Exciting discoveries in the last decade have contributed to a better understanding of the molecular basis of this disease. Epidemiological, experimental, and therapeutic studies from several laboratories have provided compelling evidence that an antiangiogenic state owing to alterations in circulating angiogenic factors leads to preeclampsia. In this review, we highlight the role of key circulating antiangiogenic factors as pathogenic biomarkers and in the development of novel therapies for preeclampsia.
子痫前期是一种妊娠特有的疾病,其特征为妊娠20周后新发高血压和蛋白尿。它是全球孕产妇和胎儿发病及死亡的主要原因。过去十年中的激动人心的发现有助于更好地理解这种疾病的分子基础。多个实验室的流行病学、实验和治疗研究提供了令人信服的证据,即循环血管生成因子的改变导致的抗血管生成状态会引发子痫前期。在本综述中,我们强调关键循环抗血管生成因子作为致病生物标志物的作用以及在子痫前期新疗法开发中的作用。